Drugs / Oligopin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03260803 | Feb → Dec 2018 | osteoporosis | Tehran University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oligopin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03260803 ↗ |
| Known as | Pine bark extract | “Pine bark extract (oligopin) is a rich source of polyphenols that exerts strong antioxidant and anti-inflammatory activities.” NCT03260803 ↗ |